Malignancy

Questions discussed in this category

What is your approach to screening for malignancy in dermatomyositis patients who do not have a high risk antibody profile and whose disease responds well to treatment?

Do you pursue screening beyond age-appropriate malignancy screening, especially in younger patients? For how long do you continue to monitor beyond th...

1 Answer available

Do you continue methotrexate in patients with inflammatory arthritis who develop non-melanomatous skin cancer while on therapy?

1 Answer available

How do you counsel patients about the malignancy risk associated with azathioprine?

1 Answer available

How do you approach evaluation of hypocomplementemia in a patient with arthralgias and a history of Hodgkin's lymphoma treated in the past?

ANA and ENA negative

1 Answer available

How do you manage dermatomyositis related to underlying malignancy?

Is there a role of immunosuppression or treating underlying malignancy will be enough?

1 Answer available

Does discovery of clonal hematopoiesis on liquid biopsy for solid tumors change your treatment approach in terms of which chemotherapy to offer for the solid tumor?

1 Answer available

Would you continue TNFi for inflammatory arthritis if the patient develops a solid organ malignancy while on that therapy?

1 Answer available

How do you approach treatment of rheumatoid arthritis in a patient with an active hematologic malignancy (such as leukemia or lymphoma) after methotrexate failure?

Does your management change if there is renal involvement of the malignancy?

2 Answers available

How would you treat uveitis in a patient with a history of cutaneous T cell lymphoma?

Patient was previously well controlled on methotrexate, which was discontinued during cancer treatment.

1 Answer available

Papers discussed in this category

British journal of cancer, 2023 Feb 04

Use of methotrexate and risk of skin cancer: a nationwide case-control study.

Nature reviews. Rheumatology, 2023 Nov 09

International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.

Malignancy

Questions discussed in this category

Papers discussed in this category

Related Topics